Lytix Biopharma has an extensive patent estate related to oncolytic peptides which provides protection of the company’s technology in key markets throughout the world.

The patent estate includes patent families covering oncolytic peptides, their production and use, pharmaceutical compositions comprising such peptides, methods of treating cancer, including reshaping of a tumor microenvironment and for inducing tumor specific immunity and combination therapies including the peptides and other therapeutic agents.

 

Disclaimer: The above is a high-level description of Lytix Biopharma AS’ patent estate and is not a statement on or an interpretation of the actual scope of the company’s patents and patent applications.